Effect of Spiriva on the Activities of Daily Living Score Recommended in Austrian COPD Guidelines

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Tiotropium

Study type: Observational

Funder types: Industry

Identifiers

NCT00615992

205.398

Details and patient eligibility

About

The primary goal of this post marketing surveillance (PMS) study is to document the efficacy of Tiotropium (Spiriva) to improve physical activity measured by a score that is recommended in national chronic obstructive pulmonary disease (COPD) guidelines for monitoring the course of the disease.

Enrollment: 754 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with suspected chronic obstructive pulmonary disease (COPD)
• 3 or more positive answers in COPD questionnaire
• Age over 40 years

Exclusion criteria

• Patients with any conditions listed in special precautions, drug interactions, and contraindication of Spiriva in the summary of product characteristics
• Patient treated with Spiriva in the past year
• Patient with history of hypersensitivity to tiotropium bromide, atropine and/or its derivant, i.e. ipratropium, or any component of Spiriva Patient with known narrow-angle glaucoma Patient with known symptomatic prostatic hyperplasia and/or bladder-neck obstruction Patient with known moderate to severe renal impairment (i.e.,creatinine clearance<=50ml/min) Pregnant or nursing women Patient with any significant disease other than COPD which would exclude him/her from participating in the study Patients with any conditions listed in special precautions, drug interactions, and contraindication of Spiriva in Austrian summary of product characteristics